GermUV-C has announced a successful completion of $ 28.8 million to $ 28.8 million to accelerate its development in the United States and to continue its development in the UV-C infection prevention technology in the United States.
The round was led by its Nave Sant Action Non Cotes Fund in the European investment group Europe. Existing shareholders also participated in the round. The financing, together with the European investment bank’s previous funds in 2021, has been in Germantech for sustainable growth in the next two years with profitability on the horizon.
“We are shocked to welcome Eurazio as a strategic investor and are equally grateful for the continued assistance of our existing shareholders“Said Vincent GuardsChief Executive Officer of Germitech. “This fund identifies an important milestone for germs because we extend our footprints in the United States and maintain our promise to develop the cutting edge sterilization that enhances patient protection and operational skillsThe “
Established in 2005, the flagship product line of Germitech provides a rapid, effective and chemical-free solution to prevent health care infections (HAI) and improve care quality.
According to Germanitech, the infectious risk is related to the quality of healthy practice surrounded by the ultrasound method (hand hygiene, treatment environment maintenance, ultrasound gel and protective sheet for probes), and sterilization of probes.
According to statistics on their website, 13% of vaginal probes used with Wipes with HPV positive, applying new infection control interfering can prevent HIIs and 15% of lower and middle-income countries can be prevented in their hospital. Will achieve at least one h in while staying.
As the global demand for infection increases, the solutions of germs are strengthened everywhere in the face of critical demand. Ultrasounds are performed everywhere: fertility (IVF), gynecology, cardiology and ear nose and throat (ENT). Thanks to UV-C technology and its availability in 40 countries, 2.2 million patients are addressed worldwide every year.
With an FDA de Novo Manzoor in August 2021 and 60K unit market opportunities in the United States, Germitech fast market shares and “fast market shares and”.Double each year’s earningsThe “
“One of the main pillars of Eurajo is to invest in the challenges of large public health. Therefore we are extremely proud to support Germitech with a mission to resist the UV-Ce high-level antibacterial solution and infection resistance to its ultrasound probes“Said Arunud VincentManaging Director – Healthcare, Europe. “Germitech’s innovative UV-C technology is integrated with our commitment to encourage the transformed healthcare solutions that improve patients and sustainability of the systemThe “
The money obtained from this finishing round will be allocated to invest in research and development for the expansion of US activities, to accelerate commercial adoption, and expansion of Germitech’s product portfolio. The aim of the organization’s efforts is to determine the new value for sterilization skills and protection in the health care industry.
[publish_date
